Press releases
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
- Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
More ▼
Key statistics
As of last trade, Rigel Pharmaceuticals Inc (RI2A:MUN) traded at 0.998, 53.78% above the 52 week low of 0.649 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.998 |
---|---|
High | 0.998 |
Low | 0.998 |
Bid | 1.03 |
Offer | 1.09 |
Previous close | 0.981 |
Average volume | 425.00 |
---|---|
Shares outstanding | 175.40m |
Free float | 171.71m |
P/E (TTM) | -- |
Market cap | 191.19m USD |
EPS (TTM) | -0.1444 USD |
Data delayed at least 15 minutes, as of May 02 2024 07:00 BST.
More ▼